Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 16 | 2025 | 404 | 3.340 |
Why?
|
| Buprenorphine | 10 | 2025 | 155 | 2.880 |
Why?
|
| Amphetamine-Related Disorders | 5 | 2024 | 93 | 2.070 |
Why?
|
| Methamphetamine | 5 | 2024 | 189 | 1.940 |
Why?
|
| Cocaine-Related Disorders | 7 | 2025 | 206 | 1.780 |
Why?
|
| Opiate Substitution Treatment | 11 | 2025 | 107 | 1.760 |
Why?
|
| Methadone | 7 | 2025 | 184 | 1.650 |
Why?
|
| Central Nervous System Stimulants | 2 | 2024 | 198 | 1.360 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2025 | 168 | 1.340 |
Why?
|
| Disulfiram | 3 | 2025 | 13 | 1.100 |
Why?
|
| Alcohol Deterrents | 2 | 2025 | 10 | 1.020 |
Why?
|
| Tai Ji | 1 | 2023 | 22 | 0.800 |
Why?
|
| Patient Discharge | 1 | 2024 | 320 | 0.730 |
Why?
|
| Dextroamphetamine | 1 | 2021 | 36 | 0.720 |
Why?
|
| Analgesics, Opioid | 6 | 2023 | 601 | 0.680 |
Why?
|
| Narcotic Antagonists | 6 | 2025 | 150 | 0.650 |
Why?
|
| Sertraline | 3 | 2017 | 47 | 0.640 |
Why?
|
| Patient Compliance | 3 | 2016 | 228 | 0.620 |
Why?
|
| Double-Blind Method | 8 | 2025 | 726 | 0.620 |
Why?
|
| Narcotics | 3 | 2025 | 109 | 0.600 |
Why?
|
| Adult | 23 | 2025 | 14205 | 0.540 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2014 | 18 | 0.530 |
Why?
|
| Amines | 2 | 2014 | 38 | 0.520 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2014 | 64 | 0.510 |
Why?
|
| Naltrexone | 2 | 2025 | 69 | 0.450 |
Why?
|
| Child Abuse | 1 | 2016 | 143 | 0.430 |
Why?
|
| Depression | 3 | 2014 | 603 | 0.430 |
Why?
|
| Male | 23 | 2025 | 26874 | 0.410 |
Why?
|
| Female | 24 | 2025 | 28277 | 0.410 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2010 | 393 | 0.400 |
Why?
|
| Methadyl Acetate | 2 | 2010 | 11 | 0.400 |
Why?
|
| Young Adult | 7 | 2024 | 4346 | 0.390 |
Why?
|
| Humans | 29 | 2025 | 52441 | 0.380 |
Why?
|
| Middle Aged | 15 | 2025 | 13133 | 0.350 |
Why?
|
| Reward | 1 | 2010 | 117 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2025 | 1365 | 0.310 |
Why?
|
| Treatment Outcome | 7 | 2025 | 5508 | 0.290 |
Why?
|
| Heart Rate | 2 | 2025 | 311 | 0.280 |
Why?
|
| Behavior Therapy | 1 | 2010 | 181 | 0.280 |
Why?
|
| Outpatients | 3 | 2025 | 128 | 0.280 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 3 | 2014 | 40 | 0.270 |
Why?
|
| Pilot Projects | 4 | 2021 | 725 | 0.260 |
Why?
|
| Cocaine | 3 | 2025 | 168 | 0.260 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2006 | 67 | 0.250 |
Why?
|
| Anxiety | 2 | 2022 | 305 | 0.220 |
Why?
|
| Health Status | 1 | 2006 | 300 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2022 | 6694 | 0.220 |
Why?
|
| Veterans | 2 | 2010 | 573 | 0.220 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 641 | 0.220 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 615 | 0.220 |
Why?
|
| Patient Admission | 1 | 2024 | 80 | 0.210 |
Why?
|
| Databases, Factual | 2 | 2019 | 721 | 0.180 |
Why?
|
| Adolescent | 4 | 2024 | 6713 | 0.180 |
Why?
|
| Time Factors | 4 | 2011 | 2987 | 0.170 |
Why?
|
| Pain | 1 | 2023 | 373 | 0.170 |
Why?
|
| Quality of Life | 1 | 2006 | 893 | 0.170 |
Why?
|
| Naloxone | 2 | 2013 | 85 | 0.160 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2021 | 333 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 255 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 444 | 0.160 |
Why?
|
| Self Report | 3 | 2016 | 221 | 0.160 |
Why?
|
| Patient Dropouts | 2 | 2016 | 52 | 0.150 |
Why?
|
| Prescription Drug Misuse | 1 | 2019 | 31 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2019 | 81 | 0.150 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2024 | 81 | 0.130 |
Why?
|
| Age Factors | 2 | 2010 | 1120 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1677 | 0.130 |
Why?
|
| Ambulatory Care | 2 | 2016 | 238 | 0.130 |
Why?
|
| Life Change Events | 1 | 2016 | 35 | 0.130 |
Why?
|
| Prevalence | 2 | 2016 | 1016 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2021 | 2433 | 0.110 |
Why?
|
| GABA Agonists | 1 | 2014 | 14 | 0.110 |
Why?
|
| Logistic Models | 1 | 2016 | 930 | 0.100 |
Why?
|
| Risk-Taking | 1 | 2014 | 114 | 0.100 |
Why?
|
| Diltiazem | 1 | 2013 | 10 | 0.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2013 | 49 | 0.100 |
Why?
|
| Verapamil | 1 | 2013 | 19 | 0.100 |
Why?
|
| Suicidal Ideation | 1 | 2014 | 110 | 0.100 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 60 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 404 | 0.100 |
Why?
|
| Suicide | 1 | 2014 | 85 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2014 | 133 | 0.100 |
Why?
|
| Motivation | 1 | 2014 | 283 | 0.090 |
Why?
|
| Recurrence | 1 | 2014 | 680 | 0.090 |
Why?
|
| Internet | 1 | 2014 | 262 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2013 | 273 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 1045 | 0.090 |
Why?
|
| Token Economy | 1 | 2010 | 33 | 0.080 |
Why?
|
| Substance Abuse Detection | 1 | 2010 | 93 | 0.080 |
Why?
|
| Affect | 1 | 2011 | 107 | 0.080 |
Why?
|
| Income | 1 | 2010 | 106 | 0.080 |
Why?
|
| Hospitals, Veterans | 1 | 2010 | 107 | 0.080 |
Why?
|
| Choice Behavior | 1 | 2010 | 82 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2011 | 324 | 0.080 |
Why?
|
| Sleep | 1 | 2011 | 191 | 0.080 |
Why?
|
| Benzhydryl Compounds | 1 | 2009 | 70 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2010 | 656 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2011 | 525 | 0.070 |
Why?
|
| Arkansas | 1 | 2014 | 2013 | 0.070 |
Why?
|
| Cognition | 1 | 2011 | 363 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 609 | 0.070 |
Why?
|
| Personality Inventory | 1 | 2006 | 50 | 0.060 |
Why?
|
| Child | 2 | 2016 | 7194 | 0.060 |
Why?
|
| Combat Disorders | 1 | 2006 | 37 | 0.060 |
Why?
|
| United States | 2 | 2024 | 5215 | 0.060 |
Why?
|
| Psychometrics | 1 | 2006 | 238 | 0.060 |
Why?
|
| Comorbidity | 1 | 2006 | 637 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2006 | 335 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2023 | 118 | 0.050 |
Why?
|
| Secondary Prevention | 2 | 2013 | 85 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2021 | 21 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 288 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2021 | 109 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 625 | 0.040 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2017 | 7 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1223 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 938 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2019 | 189 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 521 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 1349 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 2642 | 0.030 |
Why?
|
| Directly Observed Therapy | 1 | 2013 | 5 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 52 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2014 | 159 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 78 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 65 | 0.020 |
Why?
|
| Calcium Channels, L-Type | 1 | 2013 | 69 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2013 | 198 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 83 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 485 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 235 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2008 | 210 | 0.020 |
Why?
|
| Aged | 1 | 2014 | 10242 | 0.010 |
Why?
|